×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Non invasive Helicobacter Pylori Testing Market

ID: MRFR/HC/32188-HCR
100 Pages
Rahul Gotadki
October 2025

Non-invasive Helicobacter Pylori Testing Market Research Report By Test Type (Urea Breath Test, Serology Test, Fecal Antigen Test), By End User (Hospitals, Diagnostic Laboratories, Research Institutions), By Technology (Molecular Diagnostics, Immunoassays, Microbiological Testing), By Condition Type (Symptomatic Infection, Asymptomatic Infection, Post-Treatment Assessment) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Non invasive Helicobacter Pylori Testing Market Infographic
Purchase Options

Non invasive Helicobacter Pylori Testing Market Summary

As per MRFR analysis, the Non-invasive Helicobacter Pylori Testing Market was estimated at 2.374 USD Billion in 2024. The market is projected to grow from 2.51 USD Billion in 2025 to 4.375 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.71 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Non-invasive Helicobacter Pylori Testing Market is experiencing robust growth driven by technological advancements and rising health awareness.

  • Technological advancements in testing methods are enhancing the accuracy and efficiency of non-invasive diagnostics.
  • North America remains the largest market, while the Asia-Pacific region is emerging as the fastest-growing area for these testing solutions.
  • The Urea Breath Test holds the largest market share, whereas the Serology Test is witnessing the fastest growth in adoption.
  • Key market drivers include the increasing incidence of Helicobacter Pylori infections and rising health awareness promoting preventive care.

Market Size & Forecast

2024 Market Size 2.374 (USD Billion)
2035 Market Size 4.375 (USD Billion)
CAGR (2025 - 2035) 5.71%

Major Players

Abbott Laboratories (US), Roche Diagnostics (CH), Thermo Fisher Scientific (US), Siemens Healthineers (DE), F. Hoffmann-La Roche AG (CH), Biohit Oyj (FI), Helicobacter pylori Testing (US), Genomica (ES)

Non invasive Helicobacter Pylori Testing Market Trends

The Non-invasive Helicobacter Pylori Testing Market is currently experiencing notable growth, driven by an increasing awareness of gastrointestinal health and the rising prevalence of H. pylori infections globally. This market encompasses various testing methodologies, including breath tests, serological tests, and stool antigen tests, which are favored for their ease of use and patient comfort. As healthcare providers seek to enhance diagnostic accuracy while minimizing patient discomfort, the demand for non-invasive testing options appears to be on the rise. Furthermore, advancements in technology and the development of more sensitive testing kits are likely to contribute to market expansion, as they offer improved detection rates and faster results. In addition, the growing emphasis on preventive healthcare and early diagnosis is shaping the landscape of the Non-invasive Helicobacter Pylori Testing Market. Patients are increasingly seeking out non-invasive options that allow for quick and reliable results without the need for invasive procedures. This trend is further supported by healthcare policies that promote early detection and treatment of gastrointestinal disorders. As a result, the market is poised for continued growth, with innovations in testing methods and increased accessibility likely to play pivotal roles in its evolution.

Technological Advancements

Recent innovations in testing technologies are enhancing the accuracy and efficiency of non-invasive H. pylori tests. Newer methodologies are being developed that promise quicker results and improved sensitivity, which may lead to broader adoption in clinical settings.

Rising Health Awareness

There is a growing public consciousness regarding gastrointestinal health, which is driving demand for non-invasive testing options. As individuals become more informed about the implications of H. pylori infections, they are more likely to seek out testing.

Shift Towards Preventive Healthcare

The healthcare landscape is increasingly focusing on preventive measures, encouraging early diagnosis and treatment of conditions like H. pylori infections. This shift is likely to boost the demand for non-invasive testing methods that facilitate timely intervention.

Non invasive Helicobacter Pylori Testing Market Drivers

Regulatory Support and Guidelines

Regulatory support and the establishment of guidelines for Helicobacter Pylori testing are crucial factors propelling the Non-invasive Helicobacter Pylori Testing Market. Health authorities are increasingly recognizing the importance of early detection and management of Helicobacter Pylori infections, leading to the development of standardized testing protocols. These guidelines encourage healthcare providers to adopt non-invasive testing methods, which are often preferred by patients due to their convenience and safety. As regulatory bodies continue to advocate for improved testing practices, the market is likely to see enhanced adoption rates of non-invasive testing solutions. This regulatory backing not only boosts confidence among healthcare providers but also promotes patient compliance, ultimately contributing to the growth of the Non-invasive Helicobacter Pylori Testing Market.

Expansion of Healthcare Infrastructure

The expansion of healthcare infrastructure is a pivotal driver for the Non-invasive Helicobacter Pylori Testing Market. As healthcare systems evolve and improve, access to diagnostic testing becomes more widespread, particularly in underserved regions. This expansion includes the establishment of new clinics and diagnostic centers equipped with advanced testing technologies. Increased availability of non-invasive testing options is likely to enhance patient access to necessary healthcare services, thereby driving demand for Helicobacter Pylori testing. Furthermore, as healthcare providers invest in training and resources to implement these testing methods, the market is expected to experience robust growth. This trend reflects a broader commitment to improving healthcare delivery and outcomes, which is essential for the continued advancement of the Non-invasive Helicobacter Pylori Testing Market.

Rising Health Awareness and Preventive Care

The growing emphasis on health awareness and preventive care is significantly influencing the Non-invasive Helicobacter Pylori Testing Market. As individuals become more informed about the implications of Helicobacter Pylori infections, there is a marked increase in proactive health measures. This shift towards preventive healthcare is driving demand for non-invasive testing methods, as patients seek to identify potential health issues before they escalate. The market is witnessing a transformation, with healthcare providers increasingly recommending routine screenings, particularly in high-risk populations. This proactive approach not only aids in early diagnosis but also aligns with broader public health initiatives aimed at reducing the burden of gastrointestinal diseases, thereby fostering growth in the Non-invasive Helicobacter Pylori Testing Market.

Technological Advancements in Testing Methods

The Non-invasive Helicobacter Pylori Testing Market is experiencing a surge in technological advancements that enhance testing accuracy and efficiency. Innovations such as breath tests and stool antigen tests are becoming increasingly prevalent, providing reliable alternatives to invasive procedures like endoscopy. These non-invasive methods not only reduce patient discomfort but also lower the risk of complications associated with invasive testing. The market is projected to grow as these technologies become more widely adopted, with estimates suggesting a compound annual growth rate of over 8% in the coming years. As healthcare providers seek to improve patient outcomes, the integration of advanced testing technologies is likely to play a pivotal role in shaping the future of the Non-invasive Helicobacter Pylori Testing Market.

Increasing Incidence of Helicobacter Pylori Infections

The rising incidence of Helicobacter Pylori infections is a significant driver for the Non-invasive Helicobacter Pylori Testing Market. Studies indicate that nearly half of the world's population is infected with this bacterium, which is linked to various gastrointestinal disorders, including peptic ulcers and gastric cancer. As awareness of these health risks grows, there is a corresponding increase in demand for effective testing solutions. The market is responding to this need, with a projected increase in testing volumes, particularly in regions with high prevalence rates. This trend underscores the importance of accessible and non-invasive testing options, which are essential for early detection and management of infections, thereby propelling the Non-invasive Helicobacter Pylori Testing Market forward.

Market Segment Insights

By Test Type: Urea Breath Test (Largest) vs. Serology Test (Fastest-Growing)

In the Non-invasive Helicobacter Pylori Testing Market, the Urea Breath Test currently holds the largest market share among the testing methods. It is widely preferred due to its high accuracy and convenience, making it the go-to choice for both clinicians and patients. Meanwhile, the Serology Test, while slightly behind in market share, is gaining traction rapidly, showcasing the dynamics of evolving testing preferences in the healthcare sector. Growth trends within this segment indicate a notable shift towards the Serology Test, driven by advancements in technology and increasing acceptance of blood-based diagnostics. Factors contributing to this growth include enhanced awareness of Helicobacter Pylori-related conditions and the rising prevalence of gastrointestinal diseases globally. As healthcare providers seek more efficient testing methods, this segment is expected to continue evolving, paving the way for increased adoption and utilization of non-invasive testing options.

Urea Breath Test (Dominant) vs. Fecal Antigen Test (Emerging)

The Urea Breath Test stands as the dominant method in the Non-invasive Helicobacter Pylori Testing Market, praised for its non-invasive nature and highly accurate results. It utilizes a simple process whereby patients ingest a urea solution and exhale, enabling the detection of H. pylori through the analysis of exhaled breath. This method is favored in clinical practice for its quick turnaround time and minimal patient preparation. In contrast, the Fecal Antigen Test is seen as an emerging alternative, gaining popularity due to its cost-effectiveness and ease of administration. As stool sampling becomes less stigmatized and more recognized for its diagnostic capabilities, the Fecal Antigen Test is poised to grow, especially in regions where accessibility to advanced diagnostic technologies remains limited.

By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the Non-invasive Helicobacter Pylori Testing Market, hospitals capture the largest share of the end-user segment, primarily due to their extensive patient volumes and comprehensive healthcare services. These facilities utilize advanced non-invasive testing methods to enhance patient diagnosis and treatment efficiency. Conversely, diagnostic laboratories are rapidly gaining traction as the fastest-growing segment, driven by increasing demand for quick and accurate diagnostic tests. Their ability to provide focused services and technological advancements contributes to their swift expansion in this market.

End User: Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals remain the dominant end-user in the Non-invasive Helicobacter Pylori Testing Market due to their capability to integrate these testing methods into patient care pathways efficiently. They boast extensive resources and expertise to handle a wide array of medical cases, ensuring high testing volumes and better access to advanced diagnostics. Meanwhile, diagnostic laboratories represent the emerging segment, characterized by their agility and specialization in offering targeted tests that cater to healthcare providers' needs. Their growth is propelled by technological innovations and a rising emphasis on diagnostic accuracy, allowing them to effectively capitalize on the increasing demand for non-invasive testing solutions.

By Technology: Molecular Diagnostics (Largest) vs. Immunoassays (Fastest-Growing)

Within the Non-invasive Helicobacter Pylori Testing Market, the technology segment demonstrates a diverse range of testing methods, with molecular diagnostics taking the lead in terms of market share. This method, known for its accuracy and reliability, represents the bulk of market engagement. Immunoassays, especially enzyme-linked immunosorbent assays (ELISA), are rapidly gaining traction and are expected to capture an increasing share of the market as healthcare providers seek less invasive and cost-effective solutions for H. pylori detection. The growth trends in this segment are fueled by several factors, including the rising prevalence of Helicobacter Pylori infections and the demand for non-invasive testing alternatives. Moreover, technological advancements are enabling faster and more accurate testing methods. The increasing emphasis on early diagnosis and effective treatment in clinical settings is further driving the adoption of immunoassays, marking it as a fast-growing segment within this market, while molecular diagnostics remains firmly established as the dominant technology.

Technology: Molecular Diagnostics (Dominant) vs. Immunoassays (Emerging)

Molecular diagnostics represents the dominant force in the Non-invasive Helicobacter Pylori Testing Market, leveraging advanced techniques such as PCR for high sensitivity and specificity in detecting H. pylori. This segment appeals strongly to healthcare providers due to its ability to deliver rapid and reliable results, crucial for timely patient management. In contrast, immunoassays are emerging as a preferred alternative, particularly due to their non-invasive nature and cost-effectiveness. The increased adoption of these assays, including rapid tests that can be conveniently administered in various settings, underscores a significant shift towards accommodating patient preferences and streamlining healthcare delivery. This dynamic between the established molecular diagnostics and the rising prominence of immunoassays shapes the future landscape of H. pylori diagnostics.

By Condition Type: Symptomatic Infection (Largest) vs. Post-Treatment Assessment (Fastest-Growing)

The Non-invasive Helicobacter Pylori Testing Market exhibits a varied distribution among its condition type segments, with symptomatic infections leading the way due to the higher prevalence and awareness of related symptoms. These infections often prompt patients to seek testing, bolstering this segment's market share significantly. Following closely are the post-treatment assessment tests, which have gained traction as a necessary follow-up step for those undergoing treatment, contributing to their growing share in the market.

Symptomatic Infection (Dominant) vs. Post-Treatment Assessment (Emerging)

In the Non-invasive Helicobacter Pylori Testing Market, symptomatic infection testing remains the dominant segment, driven by the direct correlation between visible gastric symptoms like ulcers and the need for H. pylori diagnosis. Additionally, with an increasing number of individuals seeking testing due to awareness campaigns and rising cases of related complications, this segment's position is solidified. Conversely, post-treatment assessment testing is emerging rapidly as more healthcare providers recognize the importance of verifying the effectiveness of treatment. As guidelines evolve and emphasize the significance of confirming eradication post-therapy, the demand for these tests is anticipated to climb, establishing them as a critical aspect of H. pylori management.

Get more detailed insights about Non invasive Helicobacter Pylori Testing Market

Regional Insights

The Regional segment of the Non-invasive Helicobacter Pylori Testing Market is expected to see varying performance across different areas, reflecting local healthcare demands and advancements. North America is projected to be a major contributor, with a market value of 0.85 USD billion in 2023, expected to grow to 1.4 USD billion by 2032, showcasing its significant healthcare infrastructure and high incidence of related conditions.

Europe followed closely, valued at 0.65 USD billion in 2023 and likely reaching 1.1 USD billion by 2032, driven by stringent healthcare regulations and rising awareness among patients.

The APAC region is anticipated to experience steady growth, with figures of 0.4 USD billion in 2023 and a rise to 0.7 USD billion in 2032, attributed to the increasing prevalence of gastrointestinal disorders and technological developments.

In contrast, South America and the MEA regions held smaller market shares, with values of 0.15 USD billion and 0.07 USD billion in 2023, respectively, reflecting the emerging healthcare systems and ongoing challenges in healthcare accessibility. However, these regions present growth opportunities as awareness about non-invasive testing also begins to rise.

Overall, the Non-invasive Helicobacter Pylori Testing Market segmentation highlights diverse market dynamics influenced by region-specific factors, showcasing varied growth potential and demand.

Non-invasive Helicobacter Pylori Testing Market Regional Insights

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Non invasive Helicobacter Pylori Testing Market Regional Image

Key Players and Competitive Insights

The Non-invasive Helicobacter Pylori Testing Market is characterized by a diverse array of players striving to gain a competitive edge through innovative testing solutions and strategic collaborations. This market, which has gained significant traction due to the rising prevalence of Helicobacter pylori infections and the associated gastrointestinal disorders, reflects ongoing advancements in diagnostic technologies.

Non-invasive testing methods, such as breath and stool tests, are becoming increasingly popular due to their ease of use, accuracy, and minimal patient discomfort.

As healthcare providers and laboratories aim to enhance patient outcomes and streamline diagnostic processes, they are focusing on developing novel testing methodologies and leveraging emerging technologies to address the growing demand for efficient and reliable testing options.

Companies are also placing emphasis on expanding their geographical reach and enhancing distribution networks to capture a greater market share in this competitive landscape.

Siemens Healthineers has established a notable presence in the Non-invasive Helicobacter Pylori Testing Market through its commitment to delivering high-quality diagnostic solutions. The company is renowned for its cutting-edge technology and innovation, which significantly contribute to the efficacy and accuracy of its testing products.

Siemens Healthineers offers a comprehensive portfolio of non-invasive testing solutions that address the needs of healthcare providers and patients alike. Their focus on research and development has enabled them to introduce advanced testing modalities that can deliver rapid and reliable results.

Moreover, the brand's strong global presence and extensive distribution channels enhance its ability to reach diverse healthcare settings, thereby solidifying its position as a leader in the market. Siemens Healthineers' dedication to improving diagnostic processes ensures continued growth as it adapts to the evolving landscape of non-invasive testing.

Helicobacter pylori Test, Inc. is an emerging player in the Non-invasive Helicobacter Pylori Testing Market, particularly recognized for its specialized focus on developing and commercializing targeted H. pylori testing solutions.

The company is committed to advancing non-invasive diagnostic options, setting itself apart through its precision and ease of use. Helicobacter pylori Test, Inc. emphasizes innovative product development that meets the specific needs of clinicians and patients, thereby establishing a reputation for reliability and accuracy in testing.

Their unique approach to testing enables healthcare providers to obtain swift and definitive results, facilitating timely diagnosis and management of H. pylori infections.

By investing in educational initiatives and strategic partnerships, Helicobacter pylori Test, Inc. aims to expand its market presence and leverage its strengths in the competitive landscape of non-invasive Helicobacter pylori testing, catering to the growing demand for effective diagnostic tools.

Key Companies in the Non invasive Helicobacter Pylori Testing Market market include

Industry Developments

  • Q2 2024: Biomerica Announces CE Mark Approval for hp+detect™ Diagnostic Test for H. pylori Biomerica received CE Mark approval for its hp+detect™ non-invasive diagnostic test for Helicobacter pylori, enabling commercialization in the European Union and other regions subject to local regulatory approvals.
.webp

Future Outlook

Non invasive Helicobacter Pylori Testing Market Future Outlook

The Non-invasive Helicobacter Pylori Testing Market is projected to grow at a 5.71% CAGR from 2024 to 2035, driven by technological advancements and increasing awareness of gastrointestinal health.

New opportunities lie in:

  • Development of portable testing devices for remote diagnostics.
  • Integration of AI for enhanced test accuracy and patient management.
  • Expansion into emerging markets with tailored testing solutions.

By 2035, the market is expected to solidify its position as a leader in gastrointestinal diagnostics.

Market Segmentation

Non invasive Helicobacter Pylori Testing Market End User Outlook

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutions

Non invasive Helicobacter Pylori Testing Market Test Type Outlook

  • Urea Breath Test
  • Serology Test
  • Fecal Antigen Test

Non invasive Helicobacter Pylori Testing Market Technology Outlook

  • Molecular Diagnostics
  • Immunoassays
  • Microbiological Testing

Non invasive Helicobacter Pylori Testing Market Condition Type Outlook

  • Symptomatic Infection
  • Asymptomatic Infection
  • Post-Treatment Assessment

Report Scope

MARKET SIZE 20242.374(USD Billion)
MARKET SIZE 20252.51(USD Billion)
MARKET SIZE 20354.375(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)5.71% (2024 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Billion
Key Companies ProfiledMarket analysis in progress
Segments CoveredMarket segmentation analysis in progress
Key Market OpportunitiesAdvancements in breath and stool testing technologies enhance accuracy in the Non-invasive Helicobacter Pylori Testing Market.
Key Market DynamicsRising demand for non-invasive testing methods drives innovation and competition in the Helicobacter Pylori testing market.
Countries CoveredNorth America, Europe, APAC, South America, MEA

Leave a Comment

FAQs

What is the projected market valuation for the Non-invasive Helicobacter Pylori Testing Market in 2035?

The projected market valuation for the Non-invasive Helicobacter Pylori Testing Market in 2035 is 4.375 USD Billion.

Which companies are considered key players in the Non-invasive Helicobacter Pylori Testing Market?

Key players in the market include Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, and F. Hoffmann-La Roche AG.

What was the market valuation for the Non-invasive Helicobacter Pylori Testing Market in 2024?

The market valuation for the Non-invasive Helicobacter Pylori Testing Market in 2024 was 2.374 USD Billion.

What is the expected CAGR for the Non-invasive Helicobacter Pylori Testing Market during the forecast period 2025 - 2035?

The expected CAGR for the Non-invasive Helicobacter Pylori Testing Market during the forecast period 2025 - 2035 is 5.71%.

Which test type segment is projected to have the highest valuation by 2035?

The Urea Breath Test segment is projected to reach 1.75 USD Billion by 2035, indicating strong growth.

How do the valuations of diagnostic laboratories compare to hospitals in the Non-invasive Helicobacter Pylori Testing Market?

In 2024, diagnostic laboratories had a valuation of 0.712 USD Billion, while hospitals were valued at 0.947 USD Billion.

What is the projected valuation for the Fecal Antigen Test segment by 2035?

The Fecal Antigen Test segment is projected to reach 1.35 USD Billion by 2035.

What condition type segment is expected to show significant growth in the Non-invasive Helicobacter Pylori Testing Market?

The Symptomatic Infection segment is expected to grow to 1.75 USD Billion by 2035, reflecting its importance.

Which technology segment is anticipated to have the highest valuation by 2035?

The Immunoassays technology segment is anticipated to reach 1.25 USD Billion by 2035.

What are the projected valuations for the Asymptomatic Infection condition type segment by 2035?

The Asymptomatic Infection condition type segment is projected to reach 1.4 USD Billion by 2035.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions